vs
Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and MID PENN BANCORP INC (MPB). Click either name above to swap in a different company.
MID PENN BANCORP INC is the larger business by last-quarter revenue ($62.0M vs $44.9M, roughly 1.4× AbCellera Biologics Inc.). MID PENN BANCORP INC runs the higher net margin — 31.4% vs -19.9%, a 51.3% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs 30.8%). MID PENN BANCORP INC produced more free cash flow last quarter ($71.8M vs $-44.6M). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs 21.1%).
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
Commerce Bancorp was a Cherry Hill, New Jersey–based bank created in 1973. In 2007, it was purchased by Toronto-Dominion Bank, which merged Commerce into TD Banknorth, the latter of which was rebranded to TD Bank.
ABCL vs MPB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $44.9M | $62.0M |
| Net Profit | $-8.9M | $19.4M |
| Gross Margin | — | — |
| Operating Margin | -63.7% | 43.6% |
| Net Margin | -19.9% | 31.4% |
| Revenue YoY | 788.4% | 30.8% |
| Net Profit YoY | 73.9% | 47.0% |
| EPS (diluted) | $-0.03 | $0.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $44.9M | $62.0M | ||
| Q3 25 | $9.0M | $61.8M | ||
| Q2 25 | $17.1M | $54.3M | ||
| Q1 25 | $4.2M | $47.7M | ||
| Q4 24 | $5.0M | $47.4M | ||
| Q3 24 | $6.5M | $45.3M | ||
| Q2 24 | $7.3M | $44.1M | ||
| Q1 24 | $10.0M | $42.3M |
| Q4 25 | $-8.9M | $19.4M | ||
| Q3 25 | $-57.1M | $18.3M | ||
| Q2 25 | $-34.7M | $4.8M | ||
| Q1 25 | $-45.6M | $13.7M | ||
| Q4 24 | — | $13.2M | ||
| Q3 24 | $-51.1M | $12.3M | ||
| Q2 24 | $-36.9M | $11.8M | ||
| Q1 24 | $-40.6M | $12.1M |
| Q4 25 | -63.7% | 43.6% | ||
| Q3 25 | -851.8% | 39.3% | ||
| Q2 25 | -290.2% | 7.9% | ||
| Q1 25 | -1479.6% | 35.2% | ||
| Q4 24 | — | 34.1% | ||
| Q3 24 | -1439.4% | 32.8% | ||
| Q2 24 | -1276.2% | 32.4% | ||
| Q1 24 | -551.5% | 34.8% |
| Q4 25 | -19.9% | 31.4% | ||
| Q3 25 | -637.8% | 29.6% | ||
| Q2 25 | -203.3% | 8.8% | ||
| Q1 25 | -1077.2% | 28.8% | ||
| Q4 24 | — | 27.9% | ||
| Q3 24 | -785.4% | 27.1% | ||
| Q2 24 | -504.3% | 26.7% | ||
| Q1 24 | -408.0% | 28.7% |
| Q4 25 | $-0.03 | $0.83 | ||
| Q3 25 | $-0.19 | $0.79 | ||
| Q2 25 | $-0.12 | $0.22 | ||
| Q1 25 | $-0.15 | $0.71 | ||
| Q4 24 | — | $0.72 | ||
| Q3 24 | $-0.17 | $0.74 | ||
| Q2 24 | $-0.13 | $0.71 | ||
| Q1 24 | $-0.14 | $0.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.5M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $966.9M | $814.1M |
| Total Assets | $1.4B | $6.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $128.5M | — | ||
| Q3 25 | $83.2M | — | ||
| Q2 25 | $92.4M | — | ||
| Q1 25 | $159.3M | — | ||
| Q4 24 | $156.3M | — | ||
| Q3 24 | $126.6M | — | ||
| Q2 24 | $148.3M | — | ||
| Q1 24 | $123.6M | — |
| Q4 25 | $966.9M | $814.1M | ||
| Q3 25 | $964.0M | $796.3M | ||
| Q2 25 | $1.0B | $775.7M | ||
| Q1 25 | $1.0B | $667.9M | ||
| Q4 24 | $1.1B | $655.0M | ||
| Q3 24 | $1.1B | $573.1M | ||
| Q2 24 | $1.1B | $559.7M | ||
| Q1 24 | $1.1B | $551.0M |
| Q4 25 | $1.4B | $6.1B | ||
| Q3 25 | $1.4B | $6.3B | ||
| Q2 25 | $1.4B | $6.4B | ||
| Q1 25 | $1.3B | $5.5B | ||
| Q4 24 | $1.4B | $5.5B | ||
| Q3 24 | $1.4B | $5.5B | ||
| Q2 24 | $1.4B | $5.4B | ||
| Q1 24 | $1.5B | $5.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.7M | $80.0M |
| Free Cash FlowOCF − Capex | $-44.6M | $71.8M |
| FCF MarginFCF / Revenue | -99.4% | 115.8% |
| Capex IntensityCapex / Revenue | 21.9% | 13.3% |
| Cash ConversionOCF / Net Profit | — | 4.12× |
| TTM Free Cash FlowTrailing 4 quarters | $-174.1M | $132.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-34.7M | $80.0M | ||
| Q3 25 | $-52.6M | $26.3M | ||
| Q2 25 | $-32.4M | $29.0M | ||
| Q1 25 | $-11.6M | $11.5M | ||
| Q4 24 | $-108.6M | $51.4M | ||
| Q3 24 | $-28.9M | $16.9M | ||
| Q2 24 | $-30.0M | $18.0M | ||
| Q1 24 | $-41.7M | $12.4M |
| Q4 25 | $-44.6M | $71.8M | ||
| Q3 25 | $-61.5M | $24.3M | ||
| Q2 25 | $-45.8M | $27.2M | ||
| Q1 25 | $-22.2M | $8.8M | ||
| Q4 24 | $-187.0M | $44.5M | ||
| Q3 24 | $-47.4M | $16.8M | ||
| Q2 24 | $-50.1M | $17.7M | ||
| Q1 24 | $-65.8M | $12.1M |
| Q4 25 | -99.4% | 115.8% | ||
| Q3 25 | -687.0% | 39.4% | ||
| Q2 25 | -267.9% | 50.1% | ||
| Q1 25 | -524.0% | 18.4% | ||
| Q4 24 | -3702.8% | 93.8% | ||
| Q3 24 | -728.4% | 37.1% | ||
| Q2 24 | -683.8% | 40.2% | ||
| Q1 24 | -661.5% | 28.5% |
| Q4 25 | 21.9% | 13.3% | ||
| Q3 25 | 99.7% | 3.1% | ||
| Q2 25 | 78.2% | 3.2% | ||
| Q1 25 | 251.1% | 5.7% | ||
| Q4 24 | 1552.7% | 14.6% | ||
| Q3 24 | 284.6% | 0.0% | ||
| Q2 24 | 274.6% | 0.7% | ||
| Q1 24 | 242.5% | 0.8% |
| Q4 25 | — | 4.12× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 6.08× | ||
| Q1 25 | — | 0.84× | ||
| Q4 24 | — | 3.88× | ||
| Q3 24 | — | 1.37× | ||
| Q2 24 | — | 1.53× | ||
| Q1 24 | — | 1.02× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
